Q-omics provides the consensus-scored LDHAL6CP profile across patient tissues and cancer cell-line models. LDHAL6CP expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LDHAL6CP is differentially expressed in 3, with the highest sampling consensus in PRAD. Additionally, LDHAL6CP RNA expression shows 5,926 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, PRAD, and STAD as cancer lineages where LDHAL6CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHAL6CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHAL6CP survival associations across molecular data types. LDHAL6CP RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHAL6CP RNA expression–survival associations across cancer types. High LDHAL6CP expression shows unfavorable associations in MESO, ACC, GBM, UCEC, LGG and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify MESO as the clearest survival context for LDHAL6CP RNA expression.
This table summarizes LDHAL6CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LDHAL6CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHAL6CP shows higher tumor expression in PRAD, BRCA and STAD. The PRAD box plot shows higher LDHAL6CP RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p < 0.001).
This table shows molecular features associated with LDHAL6CP in patient tissues and cancer cell lines. In patient samples, LDHAL6CP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
